AMT shall develop genic CIMA therapy patents

January 01, 2008

The Dutch biotechnology firm Molecular Therapeutics (AMT) shall develop CIMA patents of the Navarre University, based on genic therapy. It is shown in the agreement signed with the entities handling intellectual property generated in the research center (CIMA S.L. and Digna Biotech). Actually, CIMA has around thirty patents at different development stages. Some of them are based on genic therapy, which consists, basically, on the modification of genetic material in the cells of patients to treat illnesses.

Despite it is still at experimental phase, AMT will develop patents for anti tumor treatments, leaver cancer and illnesses such as porphyria. The symptoms of this pathology appear when there are abnormalities in the production of haemo, basic substance to produce vital proteins such as hemoglobin, myoglobin and cytochrome.

Amongst the problems generated, up to date incurables, we shall remark neuro psychiatric and visceral troubles or severe abdominal pain. Besides, acute porphyria attacks can be mortal is they cause severe neurological complications.

Anti tumor Treatments
The persons affected by this illness show symptoms in intermittent periods, more or less lasting, along all their lives. Sometimes, they appear at puberty and most frequently at adult age, with more incidences on women.

“Some drugs, such as barbituric, tranquilizers or sedative, may unchain illnesses; also the slimming diets, hormonal disarrays, cigarettes, alcohol, infections or emotional and physical tensions”, explains Dr. Jesús Prieto, director of the Genetic Therapy and Hepatology of the CIMA and physician of the University Clinic of Navarre.

Besides the scientific findings based on genic therapy, there are CIMA patents addressed to fight other illnesses. Amongst the most developed ones, are antifibrotics, anti virus B and C, protectors for organ transplants and immunomodulators for cancer and infections. From all of them, the most advanced patent is P144, a molecule developed in the form of a cream for scleroderma. Other applications for P144 might be skin cancer, mammary prosthesis and cardiac fibrosis.

Some CIMA patents are shared with universities from the United States, such as California, Minnesota y Rutgers.

http://estadis.eluniversal.com.mx/finanzas/61921.html